Podium to Practice: Chicago 2026 – LUNG: OptiTROP-Lung05 study

Podium to Practice: Chicago 2026 – LUNG: OptiTROP-Lung05 study

Podium to Practice: Chicago 2026

Studies / Trials Discussed

8506 – Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.

Icon Chair Speaker

Chair

Dr. Barb Melosky

Icon Chair Speaker

Speakers

Dr. Paul Wheatley-Price

Dr. Rosalyn Juergens

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

8506 – Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
Tagged